Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
SWOG Cancer Research Network
Allogene Therapeutics
Takeda
Gamida Cell ltd
University of Chicago
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dartmouth-Hitchcock Medical Center
Hutchmed
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Brown University
Aileron Therapeutics, Inc.
Acerta Pharma BV
Eli Lilly and Company
Hoffmann-La Roche
Masonic Cancer Center, University of Minnesota
H. Lee Moffitt Cancer Center and Research Institute
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
CRISPR Therapeutics
Incyte Corporation
Children's Oncology Group
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Sanofi
Takeda
National Cancer Institute (NCI)